{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-021748","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.493003+00:00","generated_at":"2026-05-16T21:23:30.232396+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lucid Diagnostics Q3 revenue $1.2M, loss $0.10/share; key Medicare coverage step from unanimous CAC expert support","bullets":["Processed 2,841 EsoGuard tests in Q3 2025, revenue $1.2 million.","GAAP net loss $10.4M ($0.10/share); non-GAAP adjusted loss $10.3M ($0.10/share).","Cash $47.3M after $27M public offering; runway extended through 2026.","MolDx CAC meeting on Sept 4: medical experts unanimously supported Medicare coverage for EsoGuard.","Appointed Danielle Scelfo as SVP Market Access to lead payor engagement and coverage expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-021748","json":"https://secwatch.observer/filing/0001493152-25-021748.json","markdown":"https://secwatch.observer/filing/0001493152-25-021748.md","text":"https://secwatch.observer/filing/0001493152-25-021748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315225021748/0001493152-25-021748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315225021748/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:23:30.232396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}